Oriole Resources Share Discussion Threads

[juju44] 04/6/2024 08:07

Be nice if they found some gold

[flughafen17] 04/6/2024 06:17

Looks excellent.



"These latest results have provided further significant insight into the potential scale of the gold bearing system at Mbe, with the definition of three substantial targets for follow-up on the MB01 trend. MB01-S in particular is looking extremely robust, with consistently anomalous grades over a surface area of more than 0.75km2 and with a higher-grade core of over 500 ppb Au. It's also extremely encouraging to see that pit sampling has delivered grades of up to 260g/t Au outside of the previously-tested areas.

"The team has worked extremely hard to ensure that our programmes remain on schedule, and I'm pleased to report that follow-up trenching has already commenced over these three targets. This will help us to build our geological model and to guide a maiden drilling programme in the next field season.

"Results from the initial metallurgical test work are also extremely encouraging and, with a second soil sampling programme nearing completion over the wider licence area, there exists the potential for further target identification."

[adi27] 04/6/2024 06:09

RNS. Let's see what today brings!!

[luckyabbeygale] 03/6/2024 08:17

The 1.8m was a buy since it is the current buy price.

[adi27] 30/5/2024 10:36

Martin putting his hand in his pocket, and taking a decent amount of shares would help!

[luckyabbeygale] 30/5/2024 08:26

Yes your right. At least they are not like this over on the LSE Oriole forum.

[dogsoggy36] 30/5/2024 08:18

Hey Lucky don't let them get to you.ORR has the most amazing drills results coming out very soon and those holding will be laughing.

[luckyabbeygale] 30/5/2024 08:11

What about the two huge buys of over 4m each the day before yesterday?. To me it looks like there is huge support at the current price.

[luckyabbeygale] 30/5/2024 08:09

No mention of the 1m buy just before close of yesterday???.

[luckyabbeygale] 30/5/2024 08:08

I'm going to be all day posting whether you like it or not and I am a premium member so no one can stop me. 800k buy saids it all.

[dogsoggy36] 30/5/2024 07:56

That's the impression I'm getting too.The stress on his face was obvious and I think Eileen wanted to push us on more.

[juju44] 30/5/2024 07:49

Give it a rest man

[luckyabbeygale] 30/5/2024 07:46

Can sell a huge amount. The recovery is now back on again.

[adi27] 29/5/2024 21:13

Unfortunately, having seen a few underhand goings on recently with companies I've invested in I struggle to trust any of them!!

[juju44] 29/5/2024 20:18

He was pushed - useless

[adi27] 29/5/2024 19:47

Personally I feel Tim leaving has given uncertainty. I think things will be ok, but a CEO leaving when company is on the brink of big things, isn't the best. Obviously imo.

[astubbs67602] 29/5/2024 19:12

Yeah I thought we were on a bit of a comeback.......

[adi27] 29/5/2024 16:21

Big drop on nothing!!

[luckyabbeygale] 29/5/2024 11:02

Offering the full bid for up to 48 thousand pounds worth. This is the biggest tree shake I have ever seen.

[adi27] 22/5/2024 15:54

Good news and ends red, classic ORR

[citys2874] 22/5/2024 10:55

rns today


Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Aptamer and Timser partner to deliver world's first blood test for cervical cancer

Agreement for up to £465,000 signed for Optimer development

Optimer binders will be developed for use in a cervical cancer blood test



Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women's health, with a deal value of up to £465,000.



Under the terms of the agreement, Aptamer Group will develop Optimer binders to Timser's patented cervical cancer biomarker panel - a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world's first blood test for cervical cancer, preventing invasive smear tests and delivering earlier, more sensitive diagnostics.



Pairs of Optimer binders will be developed to each of the three biomarker proteins that form the unique cervical cancer signature. Timser will receive a licence for the use of the Optimers in its specific test combination, which is patented in 21 countries, including the USA.



Cervical cancer is the fourth most common cancer type in women worldwide. Present screening methods rely on invasive and relatively low sensitivity Papanicolaou (PAP) smear tests. The Optimer enabled Timser's diagnostic will allow earlier detection at the precancerous lesion stage, which is associated with increased survival. Use of a blood-based test over traditional PAP smears will offer the potential for increased detection rates by improving uptake due to the less invasive testing method.



As Timser expands its diagnostic tests into diverse markets, including low-income countries, the Optimer binders offer advantages to support continued supply and quality. With superior shelf-life and enhanced temperature stability compared to antibodies, Optimer binders facilitate global test distribution without compromising quality or performance. Previous attempts by Timser to develop antibodies to support the test have failed due to issues with antibody batch variability and supply chains. Unlike antibodies, Optimer binders are chemically manufactured, giving consistent quality, with the potential to use multiple manufacturers both locally and globally to prevent supply chain issues.





Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests."

Mercedes Gutierrez, Chief Executive Officer of TIMSER Group: "We are equally excited about this collaboration with Aptamer Group. The potential of Optimer binders to enhance the accuracy and reliability of our cancer diagnostics tests is truly promising. By integrating this advanced technology, we are confident in our ability to overcome the limitations of traditional antibodies and improve the outcomes for patients undergoing cervical cancer screening. We look forward to a successful partnership and to witnessing the impact that this new technology will have for women across the globe."

[citys2874] 22/5/2024 10:53

ORR and RTOP having a good morning ready to breakout Hopefully later today